49 results about "Non canonical" patented technology

Decoding Huffman codes is accomplished by identifying consecutive strings of high order ones or zeroes and following consecutive strings of high order ones or zeroes, retrieving a table entry for each string based on its run count and bit value, until the retrieved entry contains the decoding output symbol, or until the remaining bits of the code word number within a predetermined threshold. The remaining bits are used as an offset into a lookup table, but the dimensions of the table have been reduced through elimination of the leading ones and zeroes. The consecutive strings are preferably processed by a hardware accelerator to identify the repeated bit, count the bits in the string and return this information to the host processor. The efficiencies of decoding canonical codes are realized; yet, non-canonical codes can be decoded.

Described herein are rules to modify natural mRNAs or to engineer synthetic mRNAs to increase their translation efficiencies. These rules describe modifications to mRNA coding and 3′ UTR sequences intended to enhance protein synthesis by: 1) decreasing ribosomal diversion via AUG or non-canonical initiation codons in coding sequences, and / or 2) by evading miRNA-mediated down-regulation by eliminating one or more miRNA binding sites in coding sequences.

The invention provides methods, reagents and systems to preferentially mark fast-proliferating cells / tissues (such as cancer), by incorporating non-natural amino acids into proteins, preferably in vivo, using the endogenous protein synthesis machinery of an organism. The incorporated non-natural amino acids contain reactive groups for further chemical reagents, which may serve as a “handle” to for a number of uses, such as imaging of cancer cells, targeting drugs to preferentially kill cancer cells, and proteomic analysis in the context of large scale or high throughput screening for candidate drug leads that affects the proliferation of a target cell, etc.

Data packets on forward link packet data channels are typically transmitted at the full available power of the base station. When a non-canonical transmission format associated with a received DRC index is selected for encoding the packet data, the data may be transmitted with less that full available power, achieving the target FER due to shorter packets, and reducing system interference. The transmit power may be selected as a function of the required FER, payload size (associated physical layer format) and packet format (single- or multiple-user packet). The transmit power may also be based on the selected TF, the QoS needs of the packet data, or current system load information.

Some aspects of the present disclosure provide methods for evolving recombinases to recognize target sequences that differ from the canonical recognition sequences. Some aspects of this disclosure provide evolved recombinases, e.g., recombinases that bind and recombine naturally-occurring target sequences, such as, e.g., target sequences within the human Rosa26 locus. Methods for using such recombinases for genetically engineering nucleic acid molecules in vitro and in vivo are also provided. Some aspects of this disclosure also provide libraries and screening methods for assessing the target site preferences of recombinases, as well as methods for selecting recombinases that bind and recombine a non-canonical target sequence with high specificity.

Methods and compositions are provided for treating an individual having cancer. Aspects of the methods include administering to the individual an inhibitor of a non-canonical Notch signaling pathway gene in an amount effective to treat the cancer. Also provided are reagents, devices and kits thereof that find use in practicing the subject methods.

In accordance with the present invention, a novel aromatic prenyltransferase, Orf2 from Streptomyces sp. strain CL190, involved in naphterpin biosynthesis has been identified and the structure thereof elucidated. This prenyltransferase catalyzes the formation of a C—C bond between a prenyl group and a compound containing an aromatic nucleus, and also displays C—O bond formation activity. Numerous crystallographic structures of the prenyltransferase have been solved and refined, e.g., (1) prenyltransferase complexed with a buffer molecule (TAPS), (2) prenyltransferase as a binary complex with geranyl diphosphate (GPP) and Mg2+, and prenyltransferase as ternary complexes with a non-hydrolyzable substrate analogue, geranyl S-thiolodiphosphate (GSPP) and either (3) 1,6-dihydroxynaphthalene (1,6-DHN), or (4) flaviolin (i.e., 2,5,7-trihydroxy-1,4-naphthoquinone, which is the oxidized product of 1,3,6,8-tetrahydroxynaphthalene (THN)). These structures have been solved and refined to 1.5 Å, 2.25 Å, 1.95 Å and 2.02 Å, respectively. This first structure of an aromatic prenyltransferase displays an unexpected and non-canonical (β / α)-barrel architecture. The complexes with both aromatic substrates and prenyl containing substrates and analogs delineate the active site and are consistent with a proposed electrophilic mechanism of prenyl group transfer. These structures also provide a mechanistic basis for understanding prenyl chain length determination and aromatic co-substrate recognition in this structurally unique family of aromatic prenyltransferases. This structural information is useful for predicting the aromatic prenyltransferase activity of proteins.

Decoding Huffman codes is accomplished by identifying consecutive strings of high order ones or zeroes (216) and following consecutive strings of high order ones or zeroes, retrieving a table entry (222) for each string based on its run count and bit value, until the retrieved entry contains the decoding output symbol, or until the remaining bits of the code word number within a predetermined threshold. The remaining bits are used as an offset into a lookup table, but the dimensions of the table have been reduced through elimination of the leading ones and zeroes. The consecutive strings are preferably processed by a hardware accelerator to identify the repeated bit, count the bits in the string and return this information to the host processor. The efficiencies of decoding canonical codes are realized; yet, non-canonical codes can be decoded.

Isolated polypeptides comprising or consisting essentially of specific structural motifs (e.g., three β-sheets and two α-helices) are provided, wherein the polypeptides exhibit at least one cell signaling and / or other non-canonical activity of biological relevance. Also provided are polynucleotides encoding such polypeptides, binding agents that bind such polypeptides, analogs, variants and fragments of such polypeptides, etc., as well as compositions and methods of identifying and using any of the foregoing.

The invention discloses an inferior-quality fingerprint grayscale image enhancement method on the basis of three gaussian filtering. The method is used for studying parameter values in a three-gaussian model of a non-canonical receptive field in a human visual system according to an image characteristic that fingerprint ridges and furrows are alternately distributed and through introducing the three-gaussian model of the non-canonical receptive field in the human visual system into fingerprint grayscale image processing. The method comprises the following steps of: according to the size of a fingerprint grayscale image, obtaining fingerprint characteristic parameters; carrying out three-gaussian one-sided filtering on the fingerprint grayscale image to obtain neighborhood subjective feeling brightness of the fingerprint grayscale image; and according to a difference between the obtained neighborhood subjective feeling brightness and an actual light intensity, carrying out linear local contrast adjustment on the fingerprint grayscale image. The method disclosed by the invention can be used for effectively improving the overall and local contrast and brightness and highlighting the detail characteristics of dark areas, thus being especially applicable to the processing on inferior-quality fingerprint grayscale images.

Disclosed herein are zinc fingers comprising CCHC zinc coordinating residues. Also described are zinc finger proteins and fusion proteins comprising these CCHC zinc fingers as well as polynucleotidesencoding these proteins. Methods of using these proteins for gene editing and gene regulation are also described.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Recombinant bacterial cells are provided that comprise a stable non-canonical amino acid translation pathway. In some aspects, the bacteria comprise nucleic acids encoding a non-canonical amino acid translation pathway (e.g., a tRNA for incorporation of a non-canonical amino acid, such selenocysteine); a marker polypeptide that includes the non-canonical amino acid. Recombinant tRNA and selection marker coding sequences are likewise provided.

The present invention provides a single domain antibody (sdAb) scaffold comprising one or more than one non-canonical disulfide bond in the framework region (FR). The one or more than one non-canonical disulfide bond may be formed between cysteines introduced by mutations in FR2 and FR3. In the case where the sdAb scaffold is a VH, the Cys may be introduced at any one of positions (47-49) and any one of positions (67-71), based on Kabat numbering; in one example, the Cys may be introduced at positions (49) and (69), based on Kabat numbering. In the case where the sdAb scaffold is a VL, the Cys residues may be introduced at any one of positions 46-49 and any one of positions (62-66), based on Kabat numbering; in one example, the Cys residues may be introduced at positions (48 and 64), based on Kabat numbering.

The relationship between an amino acid sequence of a protein and its three-dimensional structure is at the very core of structural biology and bioinformatics. The occurrence and conservation of non-canonical conformations is a “local” phenomenon, i.e., non-canonical conformations are encoded intra-helically by short peptide sequences (heptapeptides at most). Effective descriptors can be formed for these short sequences employing training sets. Multiple, distinct patterns are created representing these sequences. A composite descriptor is formed by selecting from among the patterns discovered. The composite descriptor has a high level of sensitivity and specificity while, at the same time, a boosted signal-to-noise ratio.

A method and kit for synthesizing a nucleic acid molecule comprising at least one non-canonical nucleoside triphosphate using a double-mutant polymerase having a reduced discrimination between canonical and non-canonical substrates is disclosed. The method comprises incubating a template nucleic acid in a reaction mixture comprising the mutant nucleic acid polymerase and the appropriate canonical and non-canonical nucleoside triphosphates which are desired substrates for the mutant nucleic acid polymerase. The present invention is also a method of determining the sequence of a nucleic acid molecule using the mutant polymerase to create a nucleic acid molecule comprising at least one non-canonical nucleoside triphosphate.

The invention relates to a method for preventing and treating tumors by using a microRNA sponge technology. Specifically, activation of canonical and non-canonical NFkappaB pathways can be regulated through a RelA factor, thereby regulating and controlling tumor growth. According to the invention, microRNA sponge miR-221 / 222 is a RelA gene inhibitor which can substantially reduce colorectal cancer cell proliferation and in vivo tumorigenesis; miR-221 / 222 is positively correlated to colorectal cancer cell proliferation and in vivo tumorigenesis, so activation of the canonical and non-canonical NFkappaB pathways can be substantially blocked by inhibiting miR-221 / 222 highly expressed in the colorectal cancer through the microRNA sponge technology; and the RelA factor or a coding sequence thereof can be used as a target point during tumor inhibition, and the RelA factor inhibitor is used for preparing drugs for tumor prevention or treatment.

Methods of inducing a CD8+ T cell response to a heterologous antigen in which at least 10% of the CD8+ T cells are MHC-E restricted are disclosed. The method involves immunizing with a CMV vector thatdoes not express UL128 and UL130 proteins. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, a UL40 protein, and a US28 protein but that donot express an active UL128 and UL130 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active UL40 protein, UL128 protein, UL130 protein, and optionally a US28 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express anactive US28 protein, UL128 protein, UL130 protein, and optionally a UL40 protein.

The present disclosure relates to methods of treating autoimmune conditions in patients who have genetic alterations in the TNFRSF6B gene, which codes for the decoy receptor 3 protein (DcR3), for example that reduce the expression, secretion, or ligand binding activity of DcR3. For example, in some embodiments, the conditions may be treated with molecules that inhibit the activity of DcR3 ligands such as LIGHT, TL1A, and FasL, such as anti-LIGHT, anti-TL1A, and anti-FasL antibodies, or inhibitors of the non-canonical NF-κB pathway.

Provided herein are, inter alia, methods of identifying agents that are capable inhibiting the binding (e.g., coupling) between a ROR1 protein and a ROR2 protein. By interfering with ROR1-ROR2 coupling (binding) the agents identified using the methods provided herein inhibit non-canonical Wnt5a signaling. Thus, the agents identified by the methods provided herein may, inter alia, be useful for cancer diagnosis and therapy.

The present disclosure provides methods for preparing β-substituted tryptophan compounds. The methods include: combining i) an unsubstituted indole or a substituted indole, ii) a β-substituted serine, and iii) a tryptophan synthase β-subunit (i.e., a TrpB); and maintaining the resulting mixture under conditions sufficient to form the β-substituted tryptophan. The TrpB contains at least one amino acid mutation which promotes formation of an amino-acrylate intermediate. New TrpB variants and new β-substituted tryptophan analogs are also described.

A downloadable navigator for a mobile ultrasound unit having an ultrasound probe, implemented on a portable computing device. The navigator includes a trained orientation neural network to receive a non-canonical image of a body part from the mobile ultrasound unit and to generate a transformation associated with the non-canonical image, the transformation transforming from a position and rotation associated with a canonical image to a position and rotation associated with the non-canonical image; and a result converter to convert the transformation into orientation instructions for a user of the probe and to provide and display the orientation instructions to the user to change the position and rotation of the probe.

The present disclosure relates to methods of treating autoimmune conditions in patients who have genetic alterations in the TNFRSF6B gene, which codes for the decoy receptor 3 protein (DcR3), for example that reduce the expression, secretion, or ligand binding activity of DcR3. For example, in some embodiments, the conditions may be treated with molecules that inhibit the activity of DcR3 ligands such as LIGHT, TL1A, and FasL, such as anti-LIGHT, anti-TL1A, and anti-FasL antibodies, or inhibitors of the non-canonical NF-κB pathway.

Described herein are rules to modify natural mRNAs or to engineer synthetic mRNAs to increase their translation efficiencies. These rules describe modifications to mRNA coding and 3' UTR sequences intended to enhance protein synthesis by: 1) decreasing ribosomal diversion via AUG or non-canonical initiation codons in coding sequences, and / or 2) by evading miRNA-mediated down-regulation by eliminating one or more miRNA binding sites in coding sequences.

The invention discloses a method for detecting a fat coverage rate of Simmental cattle carcass by using DLK1 (Dalta Like non-canonical Notch ligand 1) gene markers. The method comprises the followingsteps: designing a pair of primers by using a DNA sequence of DLK1 gene of a Chinese Simmental cattle; performing strict PCR amplification and electrophoresis of samples on a PCR reaction system; screening and finding out two SNP sites by sequencing; screening from a population to obtain a restriction endonuclease Msp I at a DLK1-478 C / T site, wherein an excision base defined by the restriction endonuclease is CCGG; and screening to obtain a restriction endonuclease Ase I at a DLK1-609 T / G site, wherein T allele and TT mutant genotype individuals carrying the DLK1-478 C / T site in the Chinese Simmental cattle population have relatively high fat coverage rates and relatively good marbling; and G allele and GG mutant genotype individuals carrying the DLK1-609 T / G site have relatively high fatcoverage rates. According to the invention, the two mutation sites of the DLK1 gene can be used as genetic markers for predicting the fat coverage rate and marbling traits of the Chinese Simmental cattle, and are used for early marker assisted selection of beef cattle.

Recombinant nucleic acid constructs for the efficient expression of eukaryotic selenoproteins and related methods for production of recombinant selenoproteins are provided. The nucleic acid constructs comprise novel selenocysteine insertion sequence (SECIS) elements. Certain novel SECIS elements of the invention contain non-canonical quartet sequences. Other novel SECIS elements provided by the invention are chimeric SECIS elements comprising a canonical SECIS element that contains a non-canonical quartet sequence and chimeric SECIS elements comprising a non-canonical SECIS element that contains a canonical quartet sequence. The novel SECIS elements of the invention facilitate the insertion of selenocysteine residues into recombinant polypeptides.

The invention relates to a method of preparing engineered target polypeptides (TP) comprising in its amino acid sequence one or more, identical or different, non-canonical amino acid (ncAA) residues, by expressing said TP in an insect cell line (ICL) and by expressing novel orthogonal bacterial aminoacyl tRNA synthetase / tRNA pairs in said ICL; a baculoviral shuttle vector (bacmid) suitable or introducing the genetic information of said orthogonal tRNA synthetase / tRNA into said ILC; particular expression cassettes for expressing said particular tRNAs in said ILC; TPs obtained by said method; as we as a kit for preparing said TPs.

The relationship between an amino acid sequence of a protein and its three-dimensional structure is at the very core of structural biology and bioinformatics. The occurrence and conservation of non-canonical conformations is a “local” phenomenon, i.e., non-canonical conformations are encoded intra-helically by short peptide sequences (heptapeptides at most). Effective descriptors can be formed for these short sequences employing training sets. Multiple, distinct patterns are created representing these sequences. A composite descriptor is formed by selecting from among the patterns discovered. The composite descriptor has a high level of sensitivity and specificity while, at the same time, a boosted signal-to-noise ratio.

Tetrazine non-canonical amino acids, methods for genetic encoding proteins and polypeptides using the tetrazine amino acids, proteins and polypeptides comprising the tetrazine amino acids, and compositions comprising the proteins and polypeptides having at least one post-translational modification thereof comprising in vivo reaction with the incorporated tetrazine amino acid and a second molecule.